Terumo (OTCMKTS:TRUMY) Announces Quarterly Earnings Results

Key Points

• Terumo reported a quarterly earnings per share of $0.20, exceeding the consensus estimate of $0.17 by $0.03.
• The company generated $1.76 billion in revenue during the quarter, slightly below analysts' expectations of $1.80 billion.
• Following the earnings announcement, Terumo's shares fell 0.4%, bringing the stock price to $18.60.

Terumo (OTCMKTS:TRUMY - Get Free Report) posted its quarterly earnings data on Thursday, August 7th. The company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.17 by $0.03, Zacks reports. Terumo had a return on equity of 9.30% and a net margin of 12.09%. The firm had revenue of $1.76 billion during the quarter, compared to the consensus estimate of $1.80 billion.

Terumo Price Performance

OTCMKTS TRUMY traded down $0.26 during mid-day trading on Thursday, hitting $18.60. The stock had a trading volume of 73,195 shares, compared to its average volume of 180,751. The firm's 50 day moving average is $17.55 and its 200 day moving average is $18.24. Terumo has a twelve month low of $15.95 and a twelve month high of $21.22. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.00 and a quick ratio of 1.78. The stock has a market capitalization of $27.54 billion, a price-to-earnings ratio of 32.63 and a beta of 0.80.

Terumo Company Profile

Terumo Corporation engages in the manufacture and sale of medical products and equipment in Japan, Europe, China, the United States, Asia, and internationally. The company operates through three segments: Cardiac and Vascular Company, Medical Care Solutions Company, and Blood and Cell Technologies Company.